专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1994014762A1 OXIME ETHER DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY 审中-公开
标题翻译：具有LIPOXYGENASE抑制活性的OXIME醚衍生物
公开(公告)号：WO1994014762A1
公开(公告)日：1994-07-07
申请号：PCT/US1993012152
申请日：1993-12-14
申请人： ABBOTT LABORATORIES , BROOKS, Dee, W. , STEWART, Andrew, O. , MAKI, Robert, G.
发明人： ABBOTT LABORATORIES
IPC分类号： C07C259/06
CPC分类号： C07D207/335 , C07C275/64 , C07D307/58 , C07D333/22 , C07D333/58
摘要： The present invention provides certain substituted oxime ether compounds which inhibit lipoxygenase enzyme activity and are useful in the treatment of allergic and inflammatory disease states. The compounds of this invention have structure (I) where M is hydrogen, a pharmaceutically acceptable cation, or a pharmaceutically acceptable metabolically cleavable group; p and q are independently zero or one, with the proviso that (i) p and q may not both be the same; (ii) when p is one and q is zero, R is selected from the group consisting of hydrogen, straight or branched alkyl of from one to twelve carbon atoms, and cycloalkyl of from three to eight carbon atoms; and (iii) when p is zero and q is one, R is selected from the group consisting of hydrogen, alkyl of from one to twelve carbon atoms, cycloalkyl of from three to eight carbon atoms, and -NR1R2. L1 is a direct bond or is selected from the group consisting of alkyl of from one to six carbon atoms, alkylenyl, of from one to six carbon atoms, and alkynyl of from two to six carbon atoms; L2 is a direct bond or is alkyl of from one to six carbon atoms; Z is selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, and halosubstituted alkyl of from one to six carbon atoms; and A is optionally substituted carbocyclic or heterocyclic aryl, arylalkyl, or aryloxy.
摘要翻译：本发明提供某些抑制脂氧合酶活性的取代的肟醚化合物，可用于治疗过敏性和炎性疾病状态。本发明的化合物具有结构（I），其中M为氢，药学上可接受的阳离子或药学上可接受的代谢裂解基团; p和q独立为零或一个，条件是（i）p和q不能都相同; （ii）当p为1且q为0时，R选自氢，1至12个碳原子的直链或支链烷基和3至8个碳原子的环烷基; 和（iii）当p为0且q为1时，R选自氢，1至12个碳原子的烷基，3至8个碳原子的环烷基和-NR 1 R 2。 L1是直接键或选自1-6个碳原子的烷基，1至6个碳原子的亚烷基，和2至6个碳原子的炔基; L2是直接键或1-6个碳原子的烷基; Z选自氢，1至6个碳原子的烷基和1至6个碳原子的卤代烷基; 并且A是任选取代的碳环或杂环芳基，芳烷基或芳氧基。

2. 发明申请

WO1990012008A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS 审中-公开
标题翻译：基于尿素的LIPOXYGENASE抑制化合物
公开(公告)号：WO1990012008A1
公开(公告)日：1990-10-18
申请号：PCT/US1990001488
申请日：1990-03-20
申请人： ABBOTT LABORATORIES , BROOKS, Dee, W. , STEWART, Andrew, O. , SUMMERS, James, B. , KERKMAN, Daniel, J. , MARTIN, Jonathan, G.
发明人： ABBOTT LABORATORIES
IPC分类号： C07D331/00
CPC分类号： C07D409/04 , C07C275/64 , C07C323/47 , C07D333/36 , C07D335/08 , C07D409/06 , C07D409/12
摘要： Substituted phenyl, naphthyl, and thienyl N-hydroxy urea compounds form a class of potent inhibitors of 5- and 12-lipoxygenase and are thus useful compounds in the treatment of inflammatory disease states where leukotrienes and other products of lipoxygenase enzyme activity are implicated.
摘要翻译：取代的苯基，萘基和噻吩基N-羟基脲化合物形成一类5-和12-脂氧合酶的有效抑制剂，因此是治疗其中涉及白细胞三烯和其它脂氧合酶活性产物的炎性疾病状态的有用化合物。

3. 发明申请

WO2011149995A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS 审中-公开
标题翻译：新的取代的OCTAHYDROCYCLOPENTA [C]吡咯烷-4-胺作为钙通道阻断剂
公开(公告)号：WO2011149995A1
公开(公告)日：2011-12-01
申请号：PCT/US2011/037820
申请日：2011-05-24
申请人： ABBOTT LABORATORIES , SEARLE, Xenia, B. , YEUNG, Ming, C. , DIDOMENICO, Stanley , STEWART, Andrew, O. , DARCZAK, Daria , SCHRIMPF, Michael, R. , ROZEMA, Michael, J.
发明人： SEARLE, Xenia, B. , YEUNG, Ming, C. , DIDOMENICO, Stanley , STEWART, Andrew, O. , DARCZAK, Daria , SCHRIMPF, Michael, R. , ROZEMA, Michael, J.
IPC分类号： C07D209/52 , A61K31/404 , A61P29/00
CPC分类号： C07D209/52 , C07D209/02 , C07D209/44
摘要： The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L 1 , L 2 , R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
摘要翻译：本申请涉及含有式（I）化合物的钙通道抑制剂，其中L1，L2，R1，R2和R3如说明书中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

4. 发明申请

WO2010083264A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS 审中-公开
标题翻译：新型苯并呋喃二胺作为钙通道阻断剂
公开(公告)号：WO2010083264A1
公开(公告)日：2010-07-22
申请号：PCT/US2010/020964
申请日：2010-01-14
申请人： ABBOTT LABORATORIES , ZHANG, Qingwei , STEWART, Andrew, O. , XIA, Zhiren
发明人： ZHANG, Qingwei , STEWART, Andrew, O. , XIA, Zhiren
IPC分类号： C07D211/58 , C07D471/06 , C07D487/06 , A61K31/4985 , A61P25/04 , A61P25/28
CPC分类号： C07D487/04 , C07D211/58 , C07D401/04 , C07D471/04
摘要： The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), wherein L1, R1, R2, R3, R4, R5, R6, R7 and Rc are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
摘要翻译：本发明涉及包含式（I），式（II），式（III）或式（IV）的化合物的钙通道抑制剂，其中L 1，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R c 如说明书中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

5. 发明申请

WO2006081072A1 ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF 审中-公开
标题翻译： MGLU受体的拮抗剂及其用途
公开(公告)号：WO2006081072A1
公开(公告)日：2006-08-03
申请号：PCT/US2006/000967
申请日：2006-01-12
申请人： ABBOTT LABORATORIES , STEWART, Andrew, O. , ZHENG, Guo, Zhu , KOLASA, Teodozyj , BHATIA, Pramila, A. , DAANEN, Jerome, F. , LATSHAW, Steven, P. , WANG, Xueqing
发明人： STEWART, Andrew, O. , ZHENG, Guo, Zhu , KOLASA, Teodozyj , BHATIA, Pramila, A. , DAANEN, Jerome, F. , LATSHAW, Steven, P. , WANG, Xueqing
IPC分类号： C07D493/14 , C07D495/14 , C07D495/04 , A61K31/519 , A61P25/04 , A61P25/16 , A61P25/22 , A61P25/24
CPC分类号： C07D493/14 , C07D495/14
摘要： The present invention discloses compounds of general formula (I) wherein X 1 -X 4 and R 1 -R 3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.
摘要翻译：本发明公开了通式（I）的化合物，其中X 1 -X 4 -X 3和R 1 -R 3 >如说明书中所定义。本发明还公开了在有需要的宿主哺乳动物中治疗疼痛，神经变性和惊厥状态的方法，以及包括那些化合物的药物组合物。

6. 发明申请

WO2011115813A1 LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS 审中-公开
标题翻译： LACTAM ACATAMIDES作为钙通道阻断剂
公开(公告)号：WO2011115813A1
公开(公告)日：2011-09-22
申请号：PCT/US2011/027905
申请日：2011-03-10
申请人： ABBOTT LABORATORIES , DRIZIN, Irene , DOHERTY, George , BHATIA, Pramila A. , STEWART, Andrew O.
发明人： DRIZIN, Irene , DOHERTY, George , BHATIA, Pramila A. , STEWART, Andrew O.
IPC分类号： C07D211/76 , C07D401/06 , C07D401/08 , C07D401/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D403/06 , C07D471/08 , A61K31/4025 , A61K31/438 , A61K31/55 , A61K31/437 , A61K31/4545 , A61P25/00
CPC分类号： C07D211/76 , C07D401/06 , C07D401/12 , C07D403/06 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04
摘要： The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar 1 , n, R 1 , X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
摘要翻译：本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1，n，R1，X和Y如说明书中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和病症的方法。

7. 发明申请

WO2010039947A1 NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS 审中-公开
标题翻译：新型化合物作为钙通道阻塞剂
公开(公告)号：WO2010039947A1
公开(公告)日：2010-04-08
申请号：PCT/US2009/059215
申请日：2009-10-01
申请人： ABBOTT LABORATORIES , BHATIA, Pramila, A. , DOHERTY, George, A. , DRIZIN, Irene , MACK, Helmut , PERNER, Richard, J. , STEWART, Andrew, O. , ZHANG, Qing Wei
发明人： BHATIA, Pramila, A. , DOHERTY, George, A. , DRIZIN, Irene , MACK, Helmut , PERNER, Richard, J. , STEWART, Andrew, O. , ZHANG, Qing Wei
IPC分类号： C07D211/76 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D413/06 , C07D413/12 , C07D417/12 , C07D471/04 , C07D207/27 , C07D207/48 , C07D487/10 , A61K31/395 , A61P25/04 , C07D413/14
CPC分类号： C07D487/10 , C07D207/27 , C07D207/48 , C07D209/52 , C07D211/76 , C07D211/96 , C07D241/08 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar 1 , Ar 2 , L 1 , L 2 , n, R 1 , R 4 , X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
摘要翻译：本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1，Ar2，L1，L2，n，R1，R4，X和Y如说明书中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

8. 发明申请

WO1994011342A1 SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS 审中-公开
标题翻译：紫杉醇生物合成的取代的亚苄基和间二烯丙基-N-羟基脲抑制剂
公开(公告)号：WO1994011342A1
公开(公告)日：1994-05-26
申请号：PCT/US1993010675
申请日：1993-11-05
申请人： ABBOTT LABORATORIES , BASHA, Anwer , BHATIA, Pramila , BROOKS, Dee, W. , CRAIG, Richard, A. , RATAJCZYK, James, D. , STEWART, Andrew, O.
发明人： ABBOTT LABORATORIES
IPC分类号： C07C275/20
CPC分类号： C07D405/06 , C07C275/64 , C07D213/61 , C07D277/28 , C07D307/52 , C07D333/20 , C07D409/06
摘要： The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
摘要翻译：本发明涉及具有抑制脂氧合酶活性的活性的化合物，包含这些化合物的药物组合物以及治疗方法。更具体地，本发明涉及抑制白细胞三烯生物合成的某些取代的芳基炔基 - 和（（杂芳基）炔基）-N-羟基脲，这些化合物的药物组合物和抑制白三烯生物合成的方法。

9. 发明申请

WO1992001682A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY 审中-公开
标题翻译：具有LIPOXYGENASE抑制活性的乙酰衍生物
公开(公告)号：WO1992001682A1
公开(公告)日：1992-02-06
申请号：PCT/US1991004911
申请日：1991-07-11
申请人： ABBOTT LABORATORIES , BROOKS, Dee, W. , STEWART, Andrew, O. , KERKMAN, Daniel, J. , BHATIA, Pramila, A. , BASHA, Anwer
发明人： ABBOTT LABORATORIES
IPC分类号： C07D333/36
CPC分类号： C07D213/40 , C07C275/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/69 , C07D215/227 , C07D217/24 , C07D239/34 , C07D241/18 , C07D263/56 , C07D277/34 , C07D307/52 , C07D307/56 , C07D307/58 , C07D307/64 , C07D307/81 , C07D333/20 , C07D333/28 , C07D333/32 , C07D333/34 , C07D333/58 , C07D405/12 , C07D407/12 , C07D409/12
摘要： Compounds of the structure (I) where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or -NR R , where R and R are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzol[b]furyl, thienyl, or benzol[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.
摘要翻译：结构（I）的化合物，其中p和q为0或1，但不能都相同，M为药学上可接受的阳离子或代谢可裂解基团，B为价键或直链或支链亚烷基，R为烷基，环烷基或-NR 1 R 2，其中R 1和R 2是氢，烷基，环烷基或烷酰基，A是任选取代的碳环芳基，呋喃基，苯并[b]呋喃基，噻吩基或苯并[b]噻吩基是脂氧合酶的有效抑制剂，因此抑制白细胞三烯的生物合成。这些化合物可用于治疗或改善过敏性和炎性疾病状态。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式